NCT05898321View on ClinicalTrials.gov

To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone

NANot yet recruitingINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Submucous Leiomyoma of Uterus
Interventions
DRUG

Zoladex

Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.

DRUG

Mifepristone Oral Tablet

Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.

Trial Locations (1)

310000

Women's Hospital School of Medicine Zhejiang University, Hangzhou

All Listed Sponsors
lead

Women's Hospital School Of Medicine Zhejiang University

OTHER

NCT05898321 - To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone | Biotech Hunter | Biotech Hunter